Parkwalk are delighted to welcome PolyProx to its portfolio following an investment from the University of Cambridge Enterprise Fund VI.
PolyProx Therapeutics is a biotechnology company focused on the discovery and development of a new class of drugs, Polyproxin™ molecules, to treat cancer and neurodegenerative diseases. Polyproxin™ molecules are biopharmaceuticals that selectively target disease-causing proteins and use natural cellular pathways to degrade or remove these proteins.
In May 2019 the company announced that it has raised £3.4m of seed capital, which was co-led by Cambridge Innovation Capital plc (CIC), RT Capital and Cambridge Enterprise will support research operations to validate the technology across a range of tumour targets over the next two years.
